Close

Roth Capital Affirms BioBlast Pharma (ORPN) at 'Buy'; Sees Trehalose Plan Heading in Right Direction

Go back to Roth Capital Affirms BioBlast Pharma (ORPN) at 'Buy'; Sees Trehalose Plan Heading in Right Direction
Orient Paper, Inc. NEW (NASDAQ: ORPN) Delayed: 11.50 --0 (-0%)
Previous Close $11.50    52 Week High $7.95 
Open $10.61    52 Week Low $1.36 
Day High $11.50    P/E 21.30 
Day Low $11.50    EPS $0.54 
Volume 903,889